Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
Nearly 70% of ovarian cancer (OC) patients experience recurrence within the first 2 years after initial treatment. Emerging evidence indicates that long non-coding RNAs (lncRNAs) play a pivotal role in the pathogenesis of OC progression, resistance to therapy and recurrent OC (ROC). Transcriptome profiling studies have reported differential expression patterns of lncRNAs in OC which are related to increased cell invasion, metastasis and drug resistance. In this review, we highlighted the roles of lncRNAs in OC progression and outlined the potential molecular mechanisms by which lncRNAs impact on ROC. Recent advances using lncRNAs as potential biomarkers for screening, detection, prediction, response to therapy and as therapeutic targets are discussed.
['Bhardwaj|Vipul|V|', 'Tan|Yan Qin|YQ|', 'Wu|Ming Ming|MM|', 'Ma|Lan|L|', 'Zhu|Tao|T|', 'Lobie|Peter E|PE|', 'Pandey|Vijay|V|']
D000970:Antineoplastic Agents D014408:Biomarkers, Tumor D018450:Disease Progression D019008:Drug Resistance, Neoplasm D005260:Female D015972:Gene Expression Regulation, Neoplastic D006801:Humans D009364:Neoplasm Recurrence, Local D010051:Ovarian Neoplasms D057285:Precision Medicine D062085:RNA, Long Noncoding
Recurrence LncRNA ROC Metastasis Drug resistance Cancer biomarker